Our Mission

Develop and conduct Investigator-Initiated clinical trials and research about thrombosis in the United States (U.S.).

Our Impact


VENUS is the only clinical trial network in the U.S. focused solely on venous thrombosis and counts more than 128 investigators in 38+ states. As a member of the International Network of VENous Thromboembolism (INVENT), VENUS fosters international collaborative research.

  • 5-8% of the U.S. population has a genetic risk factor for VTE
  • 900,000 Americans are diagnosed with a form of VTE each year

Deep Vein Thrombosis (DVT)

Thrombosis Illustration

60,000 - 100,000

Americans die of DVT/PE each year

1/3 - 1/2 people

with DVT will experience long-term complications

Half of blood clots

occur during or soon after a hospital stay or surgery

1/3 of people

with DVT/PE will have a recurrence within 10 years

Source: Centers for Disease Control and Prevention.

About Us
VENUS initiates and implements research focused on venous thrombosis. It is also a member of the International Network of VENous Thromboembolism, or INVENT.
Get Involved
VENUS welcomes new VTE research and clinical trial collaborators from medical groups, academic institutions and research institutions across the United States.
Member Benefits
Explore research grant opportunities, VENUS meetings and conferences, and national meetings and conferences available to VENUS members.
Research and Discoveries
VENUS members have been published in a number of scientific journals and conducted anticoagulation studies benefiting patients with diseases like COVID-19.